AU2002359679B2 - Guanidinium transport reagents and conjugates - Google Patents

Guanidinium transport reagents and conjugates Download PDF

Info

Publication number
AU2002359679B2
AU2002359679B2 AU2002359679A AU2002359679A AU2002359679B2 AU 2002359679 B2 AU2002359679 B2 AU 2002359679B2 AU 2002359679 A AU2002359679 A AU 2002359679A AU 2002359679 A AU2002359679 A AU 2002359679A AU 2002359679 B2 AU2002359679 B2 AU 2002359679B2
Authority
AU
Australia
Prior art keywords
compound
group
transport
agent
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002359679A
Other languages
English (en)
Other versions
AU2002359679A1 (en
Inventor
Theodore C. Jessop
Kanaka Pattabiraman
Erin T. Pelkey
Jonathan B. Rothbard
Paul A. Wender
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CellGate Inc
Leland Stanford Junior University
Original Assignee
CellGate Inc
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CellGate Inc, Leland Stanford Junior University filed Critical CellGate Inc
Publication of AU2002359679A1 publication Critical patent/AU2002359679A1/en
Application granted granted Critical
Publication of AU2002359679B2 publication Critical patent/AU2002359679B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002359679A 2001-12-11 2002-12-11 Guanidinium transport reagents and conjugates Ceased AU2002359679B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33969601P 2001-12-11 2001-12-11
US60/339,696 2001-12-11
PCT/US2002/039698 WO2003049772A2 (en) 2001-12-11 2002-12-11 Guanidinium transport reagents and conjugates

Publications (2)

Publication Number Publication Date
AU2002359679A1 AU2002359679A1 (en) 2003-06-23
AU2002359679B2 true AU2002359679B2 (en) 2009-01-08

Family

ID=23330202

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002359679A Ceased AU2002359679B2 (en) 2001-12-11 2002-12-11 Guanidinium transport reagents and conjugates

Country Status (7)

Country Link
US (1) US7169814B2 (enExample)
EP (1) EP1461084A2 (enExample)
JP (1) JP2005538035A (enExample)
AU (1) AU2002359679B2 (enExample)
CA (1) CA2469336C (enExample)
MX (1) MXPA04005611A (enExample)
WO (1) WO2003049772A2 (enExample)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1301213B1 (en) * 2000-07-21 2017-01-18 ReVance Therapeutics, Inc. Multi-component biological transport systems
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US6969514B2 (en) * 2003-02-05 2005-11-29 Soll David B Method for treating elevated intraocular pressure, including glaucoma
JP2006524232A (ja) 2003-03-17 2006-10-26 アルバニー モレキュラー リサーチ インコーポレーティッド 新規サイクロスポリン
ES2351976T3 (es) * 2003-04-29 2011-02-14 Avi Biopharma, Inc. Composiciones para mejorar el transporte y la eficacia antisentido de análogos de ácidos nucleicos en células.
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
EP2656859B1 (en) 2004-03-03 2015-10-21 ReVance Therapeutics, Inc. Topical application and transdermal delivery of botulinum toxins
AU2005251676B2 (en) 2004-03-03 2011-09-29 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
GB0413613D0 (en) * 2004-06-17 2004-07-21 Univ London Small molecule carriers
WO2006010084A2 (en) * 2004-07-06 2006-01-26 Segev Laboratories Limited A system for delivering therapeutic agents into living cells and cell nuclei
US8680062B2 (en) 2004-07-06 2014-03-25 Deliversir Ltd. System for delivering therapeutic agents into living cells and cells nuclei
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
EP1809656A4 (en) 2004-09-29 2009-03-25 Amr Technology Inc CYCLOSPORINAL KINANALOGA AND ITS PHARMACEUTICAL APPLICATIONS
JP2008515886A (ja) 2004-10-06 2008-05-15 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキンおよびそれらの医用薬剤としての有用性
US7442682B2 (en) 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
US8022179B2 (en) * 2005-03-03 2011-09-20 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of an oligopeptide
US9180081B2 (en) * 2005-03-03 2015-11-10 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
GB2427360A (en) * 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
WO2007038172A2 (en) * 2005-09-23 2007-04-05 Nitto Denko Corporation Guanidinium carriers
US7700565B2 (en) 2005-09-23 2010-04-20 Nitto Denko Corporation Peptide nucleic acid based guanidinium compounds
US7745392B2 (en) 2005-09-23 2010-06-29 Nitto Denko Corporation Multi-valent guanidinium compounds for enhancing molecular translocation across cellular membranes and epithelial tissues
CN103126971A (zh) * 2005-11-17 2013-06-05 雷文斯治疗公司 减少非毒素蛋白质的肉毒杆菌毒素组合物和其局部施用及透皮递送方法
US8628756B2 (en) * 2005-12-30 2014-01-14 Revance Therapeutics, Inc. Arginine heteromers for topical administration
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US9375499B2 (en) * 2006-07-14 2016-06-28 Wisconsin Alumni Research Foundation Adsorptive membranes for trapping viruses
EP2068936B1 (en) * 2006-09-27 2016-06-22 Paolo Botti Means and methods of enhancing delivery to biological systems
EP1905454A1 (en) * 2006-09-27 2008-04-02 Paolo Botti Formulations comprising cyclic compounds
JP2010514779A (ja) * 2006-12-29 2010-05-06 ルバンス セラピュティックス インク． 逆配列ｈｉｖ−ｔａｔポリペプチドを用いる輸送分子
CN102988995A (zh) * 2006-12-29 2013-03-27 雷文斯治疗公司 用源自hiv-tat的多肽片段稳定的肉毒杆菌毒素的组合物及其局部施用和透皮递送的方法
US9260476B2 (en) 2007-02-23 2016-02-16 The Research Foundation For The State University Of New York RNA targeting compounds and methods for making and using same
CA2678967C (en) * 2007-02-23 2013-10-01 The Research Foundation Of State University Of New York Rna targeting compounds and methods for making and using same
US9156865B2 (en) 2007-04-23 2015-10-13 Deliversir Ltd System for delivering therapeutic agents into living cells and cells nuclei
WO2008129548A2 (en) * 2007-04-23 2008-10-30 Segev Laboratories Limited A system for delivering therapeutic agents into living cells and cells nuclei
US9556210B2 (en) 2007-04-23 2017-01-31 Sabag-Rfa Ltd. System for delivering therapeutic agents into living cells and cells nuclei
WO2009005793A2 (en) * 2007-06-29 2009-01-08 Avi Biopharma, Inc. Tissue specific peptide conjugates and methods
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
ES2805225T3 (es) * 2007-07-26 2021-02-11 Revance Therapeutics Inc Péptidos antimicrobianos y composiciones de los mismos
US7842762B2 (en) * 2007-08-08 2010-11-30 Ppg Industries Ohio, Inc. Electrodepositable coating composition containing a cyclic guanidine
WO2009099636A1 (en) * 2008-02-07 2009-08-13 The Board Of Trustees Of The Leland Stanford Junior University Conjugation of small molecules to octaarginine transporters for overcoming multi-drug resistance
US20100143437A1 (en) * 2008-12-09 2010-06-10 Morris Edward J Implantable analgesic
WO2010111533A2 (en) * 2009-03-25 2010-09-30 Kai Pharmaceuticals, Inc. Transdermal delivery of pkc modulatory peptides through microporated skin
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
EP2563380B1 (en) 2010-04-26 2018-05-30 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
AU2011248614B2 (en) 2010-04-27 2017-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
WO2011139853A2 (en) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
AU2011248457B2 (en) 2010-04-29 2017-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl tRNA synthetases
CA2797374C (en) 2010-04-29 2021-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
CN103096912A (zh) 2010-05-03 2013-05-08 Atyr医药公司 与苯丙氨酰-α-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
AU2011248230B2 (en) 2010-05-03 2016-10-06 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetases
US8961961B2 (en) 2010-05-03 2015-02-24 a Tyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases
US9062302B2 (en) 2010-05-04 2015-06-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex
AU2011252990B2 (en) 2010-05-14 2017-04-20 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
CA2800375C (en) 2010-05-27 2021-03-09 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
US8962560B2 (en) 2010-06-01 2015-02-24 Atyr Pharma Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Lysyl-tRNA synthetases
WO2012021247A2 (en) 2010-07-12 2012-02-16 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
AU2011293294B2 (en) 2010-08-25 2016-03-24 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
WO2013036532A1 (en) * 2011-09-06 2013-03-14 The Board Of Trustees Of The Leland Stanford Junior University Amphipathic co-oligomers for the delivery of sirna
US9816066B2 (en) 2012-04-24 2017-11-14 The Regents Of The University Of California Method for delivery of small molecules and proteins across the cell wall of algae using molecular transporters
CN102863357B (zh) * 2012-09-20 2014-01-01 华中农业大学 具有植物生长调节活性的化合物及其制备方法
EP2908864B1 (en) 2012-10-22 2019-12-11 Sabag-Rfa Ltd. Phosphate compounds for delivering therapeutic agents into living cells and cells nuclei
CA2889833A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
US9068089B2 (en) 2013-03-15 2015-06-30 Ppg Industries Ohio, Inc. Phenolic admix for electrodepositable coating composition containing a cyclic guanidine
US9688874B2 (en) 2013-10-25 2017-06-27 Ppg Industries Ohio, Inc. Method of making a bicyclic guanidine-cured acrylic coating
SI3149025T1 (sl) 2014-05-21 2019-09-30 Entrada Therapeutics, Inc. V celico prodirajoči peptidi in postopki njihove izdelave in uporabe
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US10383912B2 (en) * 2014-08-18 2019-08-20 Washington State University Tunable pH-sensitive linker for controlled drug release
US10456443B2 (en) 2014-08-27 2019-10-29 Ohio State Innovation Foundation Peptidyl calcineurin inhibitors
US9854806B2 (en) 2015-05-19 2018-01-02 International Business Machines Corporation Antimicrobial guanidinium and thiouronium functionalized polymers
WO2016196897A1 (en) 2015-06-04 2016-12-08 Sarepta Therapeutics, Inc. Methods and compounds for treatment of lymphocyte-related diseases and conditions
CN115252807A (zh) * 2016-07-27 2022-11-01 利兰斯坦福初级大学董事会 用于核酸递送的解体型细胞穿透性复合物
LT3554553T (lt) 2016-12-19 2022-08-25 Sarepta Therapeutics, Inc. Egzoną šalinantys oligomero konjugatai nuo raumenų distrofojos
CA3063717C (en) 2017-05-19 2021-08-24 Lunella Biotech, Inc. Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
WO2019070962A1 (en) 2017-10-04 2019-04-11 Ohio State Innovation Foundation BICYCLIC PEPTIDE INHIBITORS
CA3083487A1 (en) 2017-12-01 2019-06-06 Lunella Biotech, Inc. Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
US11576946B2 (en) 2018-01-29 2023-02-14 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-NFAT interaction
US11793884B2 (en) 2018-01-29 2023-10-24 Ohio State Innovation Foundation Cyclic peptidyl inhibitors of CAL-PDZ binding domain
CA3092062A1 (en) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
CN119220109A (zh) 2018-03-30 2024-12-31 贝克顿·迪金森公司 含侧基发色团的水溶性聚合染料
US11987647B2 (en) 2018-05-09 2024-05-21 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
KR102167755B1 (ko) 2018-05-23 2020-10-19 주식회사 큐어바이오 단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도
WO2020069013A1 (en) 2018-09-27 2020-04-02 BioPhysics Pharma, Inc. Transdermal drug delivery system
US10953039B2 (en) 2018-09-27 2021-03-23 International Business Machines Corporation Utilizing polymers and antibiotics to enhance antimicrobial activity and inhibit antibiotic resistance
US12246098B2 (en) 2018-09-27 2025-03-11 BioPhysics Pharma, Inc. Trans-epithelial membrane drug delivery system
CA3128476A1 (en) * 2019-02-01 2020-08-06 The Board Of Trustees Of The Leland Stanford Junior University Immolative cell-penetrating complexes for nucleic acid delivery to the lung
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
JP2023532736A (ja) * 2020-07-02 2023-07-31 ユニバーシティー オブ ヒューストン システム 血液脳関門を通過する薬物送達のための化合物
JP2023553815A (ja) 2020-11-24 2023-12-26 ライエル・イミュノファーマ・インコーポレイテッド 幼若化したｔ細胞を作製する方法、それを含む組成物、及びその使用方法
CA3216162A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
WO2023023527A1 (en) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
EP4155349A1 (en) 2021-09-24 2023-03-29 Becton, Dickinson and Company Water-soluble yellow green absorbing dyes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4004074A (en) * 1968-06-18 1977-01-18 Colgate-Palmolive Company Highly substantive sunscreening agents
DE3310337A1 (de) * 1983-03-22 1984-09-27 Europäisches Laboratorium für Molekularbiologie (EMBL), 6900 Heidelberg Verfahren zur durchfuehrung von hybridisierungsreaktionen
US5723496A (en) * 1991-03-05 1998-03-03 The Regents Of University Of California Method for prevention and treatment of harmful effects of intracellular acidosis
JP2651317B2 (ja) * 1992-06-18 1997-09-10 扶桑薬品工業株式会社 核酸の検出法
CA2264012C (en) * 1996-08-13 2011-04-26 Chiron Corporation Compositions and methods for polynucleotide delivery
KR20010012809A (ko) * 1997-05-21 2001-02-26 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 생체막을 통한 수송을 증진시키는 조성물 및 방법
AUPP584298A0 (en) * 1998-09-14 1998-10-08 Starpharma Limited Antimicrobial and antiparasitic agents
IL127773A0 (en) * 1998-12-28 1999-10-28 Yeda Res & Dev Saccharide conjugates and pharmaceutical compositions comprising them
US6593466B1 (en) * 1999-07-07 2003-07-15 Isis Pharmaceuticals, Inc. Guanidinium functionalized nucleotides and precursors thereof
US6730293B1 (en) * 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
US6593292B1 (en) * 1999-08-24 2003-07-15 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
JP2005508832A (ja) * 2001-02-16 2005-04-07 セルゲイト， インコーポレイテッド 間隔を開けてアルギニン部分を含むトランスポーター

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Wender Paul et al, PNAS, Vol 97, no 24, 21 November 2000. *

Also Published As

Publication number Publication date
EP1461084A2 (en) 2004-09-29
US20030185788A1 (en) 2003-10-02
JP2005538035A (ja) 2005-12-15
US20040161405A9 (en) 2004-08-19
CA2469336C (en) 2013-06-11
AU2002359679A1 (en) 2003-06-23
US7169814B2 (en) 2007-01-30
MXPA04005611A (es) 2005-04-19
WO2003049772A3 (en) 2003-11-20
WO2003049772A2 (en) 2003-06-19
CA2469336A1 (en) 2003-06-19

Similar Documents

Publication Publication Date Title
AU2002359679B2 (en) Guanidinium transport reagents and conjugates
ES2210761T3 (es) Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas.
AU2002306500B2 (en) Transporters comprising spaced arginine moieties
US7935816B2 (en) Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo
ES2834916T3 (es) Agente terapéutico dirigido de dendrímero de polilisina
EP1466627A1 (en) Polyglutamate camptothecin conjugates
JP2006507322A (ja) 多重自己脱離放出スペーサーとして構築されたプロドラッグ
AU2002306500A1 (en) Transporters comprising spaced arginine moieties
EP1263469A1 (en) Compositions and methods for enhancing drug delivery across biological membranes and tissues
JP2011523415A (ja) 新規な二重標的化抗腫瘍複合体
Lu et al. Preparation, characterization, and in vitro efficacy of O-carboxymethyl chitosan conjugate of melphalan
EP1304122A2 (en) Composition and method for enhancing transport across biological membrane
CZ406699A3 (cs) Farmaceutický prostředek a způsob zvýšení transportu vybraných sloučenin přes biologickou membránu
MXPA99010704A (en) Composition and method for enhancing transport across biological membranes
HK1155363A (en) Novel dual targeting antitumoural conjugates
HK1070570A (en) Polyglutamate camptothecin conjugates

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired